Sit Less, Interact and Move More (SLIMM) 2 Study

Recruiting

I'm Interested

Trial ID: NCT05173714

Age - 20 Years-N/A Gender - All Accepting Healthy Volunteers - No

Purpose

- Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. - In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. - Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. - This NIH funded study is conducted at the University of Utah and Stanford University. - The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Official Title

Sit Less, Interact and Move More (SLIMM) 2 Study

Stanford Investigator(s)

Glenn M. Chertow
Glenn M. Chertow

Norman S. Coplon/Satellite Healthcare Professor of Medicine and Professor, by courtesy, of Epidemiology and Population Health and of Health Policy

Eligibility


Inclusion Criteria:

   - Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate
   (eGFR) 20 to <60 mL/min/1.73m^2

   - Able to perform resistance training

   - Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with
   internet connectivity or mobile network), desktop or laptop

Exclusion Criteria:

   - Type 1 Diabetes

   - History of gastroparesis or paralytic ileus

   - At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer

   - Potential contraindications to semaglutide such as a history of pancreatitis, and a
   family or personal history of multiple endocrine neoplasia type 2 or familial
   medullary thyroid carcinoma.

   - Previous bariatric surgery

   - Medical condition likely to limit survival to less than 1 year

   - Anticipated start of dialysis or kidney transplantation within 6 months

   - Any factors judged by the investigator or study team to likely limit adherence to
   interventions

   - Vulnerable populations- pregnant or incarcerated

   - Enrolled in interventional trials using drugs or devices

   - Not able to undergo informed consent

   - Recent hospitalizations or major interventional procedures done within the past 60
   days

   - Known or suspected hypersensitivity to tegaderm

   - Use of any GLP-1 receptor agonist within 30 days prior to screening

   - Presently classified as being in New York Heart Association (NYHA) Class IV Heart
   Failure

   - Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen
   system)

   - Presence of metastatic cancer

   - Current use of mobility aid(s)

   - Living in the same household of a participant already enrolled in the study

View More
View Less

Intervention(s):

behavioral: SLIMM

behavioral: Standard Resistance Training

behavioral: Guided Resistance Training

drug: Placebo

drug: Semaglutide

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Edison Lee
650-497-7526

©2024 Stanford Medicine